Solid Biosciences: De-Risking Duchenne Program and Advancing Gene Therapy Pipeline Supports Buy Rating and $19 Target

In a report released today, Gil Blum from Needham maintained a Buy rating on Solid Biosciences, with a price target of $19.00.

Gil Blum has given his Buy rating due to a combination of factors tied to Solid Biosciences’ clinical pipeline and execution. Following the FY:25 update, he highlights that the company is keeping development of all three active programs—SGT-003 for Duchenne muscular dystrophy, SGT-501 for CPVT, and SGT-212 for FA—on the timelines previously communicated, reinforcing confidence in management’s ability to deliver.

Blum also points to SGT-003 data presented at MDA 2026, where the therapy showed strong dystrophin expression, a signal he views as meaningfully differentiating. With a planned FDA meeting in 1H:26 to pursue an accelerated approval path and the prospect of functional readouts from the INSPIRE DUCHENNE study in 2H:26 that could further reduce program risk, he sees sufficient upside to justify maintaining a Buy rating and a $19 price target.

According to TipRanks, Blum is a 4-star analyst with an average return of 8.0% and a 38.79% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Solid Biosciences, and Mereo Biopharma Group Plc.

In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $15.00 price target.